Zobrazeno 1 - 10 of 23 pro vyhledávání: '"Marian van de Meent"'
1
Akademický článek
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
Autor: Rosa A. van Amerongen, Sander Tuit, Anne K. Wouters, Marian van de Meent, Sterre L. Siekman, Miranda H. Meeuwsen, Tassilo L. A. Wachsmann, Dennis F. G. Remst, Renate S. Hagedoorn, Dirk M. van der Steen, Arnoud H. de Ru, Els M. E. Verdegaal, Peter A. van Veelen, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk
Publikováno v: Frontiers in Immunology, Vol 14 (2023)
Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ova
Externí odkaz: https://doaj.org/article/97169a79cc174ce282d2474ef1bf87ec
Zobrazit plný text záznamu
3
Akademický článek
Successful generation of primary virus-specific and anti-tumor T-cell responses from the naïve donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells
Autor: Inge Jedema, Marian van de Meent, Jeanette Pots, Michel G.D. Kester, Martha T. van der Beek, J.H. Frederik Falkenburg
Publikováno v: Haematologica, Vol 96, Iss 8 (2011)
Background One of the major challenges in allogeneic stem cell transplantation is to find a balance between the harmful induction of graft-versus-host disease and the beneficial graft-versus-leukemia and pathogen-specific immune responses. Adoptive t
Externí odkaz: https://doaj.org/article/86926a1a2ee24edf8c0423f5f761b0e8
Zobrazit plný text záznamu
4
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma
Autor: Rosa A van Amerongen, Renate S Hagedoorn, Dennis F G Remst, Danique C Assendelft, Dirk M van der Steen, Anne K Wouters, Marian van de Meent, Michel G D Kester, Arnoud H de Ru, Marieke Griffioen, Peter A van Veelen, J H Frederik Falkenburg, Mirjam H M Heemskerk
Publikováno v: Journal for ImmunoTherapy of Cancer, 10(6). BMJ PUBLISHING GROUP
BackgroundTranscription factor Wilms’ tumor gene 1 (WT1) is an ideal tumor target based on its expression in a wide range of tumors, low-level expression in normal tissues and promoting role in cancer progression. In clinical trials, WT1 is targete
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33aefaf77c54078338e2d6d6ab066927
https://hdl.handle.net/1887/3480411
Zobrazit plný text záznamu
6
Immune surveillance by autoreactive CD4-positive helper T cells is a common phenomenon in patients with acute myeloid leukemia
Autor: Inge Jedema, Marian van de Meent, Erik W.A. Marijt, T.S. Lam, J.H. Frederik Falkenburg
Publikováno v: European Journal of Haematology, 101(5), 665-675
Objectives The importance of autologous T-cell responses in immune surveillance against acute myeloid leukemia (AML) remains unclear. Therefore, we investigated the presence and functional reactivity of autoreactive T-cell responses against autologou
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fd631e81d4c784e49f0b5d8089435cc
https://doi.org/10.1111/ejh.13157
Zobrazit plný text záznamu
7
High Mutation Frequency of the PIGA Gene in T Cells Results in Reconstitution of GPI Anchor−/CD52− T Cells That Can Give Early Immune Protection after Alemtuzumab-Based T Cell–Depleted Allogeneic Stem Cell Transplantation
Autor: Wesley Huisman, Sabrina A.J. Veld, Lois Hageman, Floris C. Loeff, Inge Jedema, H. M. Esther van Egmond, J.H. Frederik Falkenburg, Hendrik Veelken, Marian van de Meent, Constantijn J.M. Halkes, Peter A. von dem Borne
Publikováno v: Journal of Immunology, 200(6), 2199-2208. AMER ASSOC IMMUNOLOGISTS
Journal of Immunology, 200(6), 2199-2208
Alemtuzumab (ALM) is used for T cell depletion in the context of allogeneic hematopoietic stem cell transplantation (alloSCT) to prevent acute graft-versus-host disease and graft rejection. Following ALM-based T cell–depleted alloSCT, relatively ra
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74ef546106834f3bcf5638b773f6a0d1
https://doi.org/10.4049/jimmunol.1701018
Zobrazit plný text záznamu
8
Mismatched HLA-DRB3 Can Induce a Potent Immune Response After HLA 10/10 Matched Stem Cell Transplantation
Autor: Inge Jedema, Constantijn J.M. Halkes, Peter van Balen, Marian van de Meent, J.H. Frederik Falkenburg, Cornelis A.M. van Bergen, Simone A.P. van Luxemburg-Heijs
Publikováno v: Transplantation, 101(12), 2850-2854
Background Donors for allogeneic stem cell transplantation are preferentially matched with patients for HLA-A, -B, -C, and -DRB1. Mismatches between donor and patient in these alleles are associated with an increased risk of graft-versus-host disease
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::393ba4fb7649cc67d3d8693733b105bf
http://hdl.handle.net/1887/115707
Zobrazit plný text záznamu
9
microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients
Autor: Sybren L. Meijer, Kausilia K. Krishnadath, Jacques J. Bergman, Francesca Milano, Silvia Calpe, Maria del Carmen Sancho Serra, Sanne Hoefnagel, S S Gisbertz, Luigi Mari, Marian van de Meent, Maarten C.C.M. Hulshof, Mirjam H.M. Heemskerk, Jan Paul Medema, Mark I. van Berge Henegouwen, Domenico Zito, Hanneke W. M. van Laarhoven, Peter van Endert
Publikováno v: Gastroenterology, 155(3), 784-798
Gastroenterology, 155(3), 784-798. W.B. Saunders Ltd
Background & Aims Immune checkpoint inhibition may affect growth or progression of highly aggressive cancers, such as esophageal adenocarcinoma (EAC). We investigated the regulation of expression of major histocompatibility complex, class 1 (MHC-I) p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26f675d0407717b91f6aa51b3b94fae7
https://pubmed.ncbi.nlm.nih.gov/29885883
Zobrazit plný text záznamu
10
High Mutation Frequency of the
Autor: Floris C, Loeff, J H Frederik, Falkenburg, Lois, Hageman, Wesley, Huisman, Sabrina A J, Veld, H M Esther, van Egmond, Marian, van de Meent, Peter A, von dem Borne, Hendrik, Veelken, Constantijn J M, Halkes, Inge, Jedema
Publikováno v: Journal of immunology (Baltimore, Md. : 1950). 200(6)
Alemtuzumab (ALM) is used for T cell depletion in the context of allogeneic hematopoietic stem cell transplantation (alloSCT) to prevent acute graft-versus-host disease and graft rejection. Following ALM-based T cell-depleted alloSCT, relatively rapi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::53a4dac83ed04e222179d90d879e5f37
https://pubmed.ncbi.nlm.nih.gov/29427418
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje